News about "Merck"

Merck Signs Exclusive License Deal for HRS-5346 with Hengrui Pharma

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Merck | 26/03/2025 | By Aishwarya |  113

Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.

Merck | 19/12/2024 | By Aishwarya |  206

Merck Signs MoU with Siemens to Accelerate Digital Transformation Technology

The MoU makes Siemens a preferred global supplier and strategic partner for Smartfacturing technologies, paving the way for transformative projects across Merck's three business sectors.

Merck | 18/09/2024 | By Aishwarya |  255

Merck to Acquire CN201 from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Merck | 14/08/2024 | By Aishwarya |  147

Merck Acquires Mirus Bio to Advance Viral Vector Bioprocessing

Merck has completed the acquisition of Mirus Bio for approximately USD 600 million (around EUR 550 million), following regulatory clearances and the fulfillment of other customary closing conditions.

Merck | 03/08/2024 | By Aishwarya |  284

Merck Signs MoU with Gene Therapy Research Institution

Merck has signed a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors.

Merck | 25/07/2024 | By Aishwarya |  265

Merck Begins Commercial Production of GMP-Compliant Manufacturing Line for CCM in China

Merck has started the commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell culture media (CCM) in China.

Merck | 16/07/2024 | By Aishwarya |  266

Merck Announces Update on Xevinapant Program in Locally Advanced Head and Neck Cancer

Merck has discontinued the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Merck | 27/06/2024 | By Aishwarya |  175

Merck Signs MoU with KAIST to Boost Scientific Research

Merck has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).

Merck | 31/05/2024 | By Aishwarya |  129

Merck Announces Acquisition of EyeBio

Merck has signed a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Merck | 30/05/2024 | By Aishwarya |  255